Stanford scientists have developed fully human CD19-targeted CAR T cells designed to overcome the limitations of current CAR T cell therapies, particularly in treating low CD19 density blood cancers.
Stanford researchers have developed a novel, multi-specific chimeric antigen receptor (CAR) T-cell therapy designed to overcome the key challenges of treating solid tumors, including tumor heterogeneity, immune evasion, and CAR T-cell exhaustion.
Stanford researchers in Prof. Michelle Monje's lab have developed a method for treating cognitive impairment (aka brain fog) caused by cancer immunotherapy.
Stanford researchers have developed a highly effective B7-H3 chimeric antigen receptor (CAR) for CAR-T cell therapy, designed to enhance binding and cytotoxicity against B7-H3 expressing solid tumors, offering a promising treatment for various cancers.
Scientists in Dr. Howard Chang's lab have developed ESCAPE-seq (Enhanced Single Chain Antigen Presentation sequencing) to identify novel neoantigen sequences for the development of immunotherapies.
Stanford researchers have defined subgroups of regulatory T cell (Tregs), CD39+ and CD39-, that can be genetically engineered to produce enhanced or reduced cytotoxicity without affecting their ability to suppress the immune system.
Stanford scientists have discovered that the untranslated region (UTR) of RNA can be engineered into autonomous switches capable of both sensing native biological conditions (e.g.
Stanford researchers have engineered retroviral and virus-like delivery systems for producing universal pseudotyped vehicles for cell and gene therapies.
A team of Stanford researchers has identified a group of small molecules that can prevent or reverse T cell exhaustion, thereby increasing the effectiveness of adoptive T cell therapies to fight cancer or chronic infections.
Researchers at Stanford, led by Prof. Crystal Mackall and Prof. Jennifer R Cochran, have developed a unique approach to cancer treatment by tackling both the innate and adaptive immune systems.
Stanford researchers in the Wu Lab have developed hypoallergenic and immunogenic induced pluripotent stem cells that could be used as a cancer treatment or prophylactic.
Despite their cytotoxic capacity, neutrophils are often co-opted by cancers to promote immunosuppression, tumor growth, and metastasis. Consequently, these cells have received little attention as potential cancer immunotherapeutic agents.